Our Parkinson's Place: BrainStorm Expands Patent Coverage of NurOwn Therapy for ALS, Parkinson’s

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Monday, October 30, 2017

BrainStorm Expands Patent Coverage of NurOwn Therapy for ALS, Parkinson’s

OCTOBER 30, 2017 BY ALICE MELÃO

BrainStorm Cell Therapeutics is expanding the patent portfolio that protects its NurOwntechnology for the treatment of several diseases affecting the central nervous system. The latest U.S. patent claim includes Parkinson’s disease and ALS (amyotrophic lateral sclerosis).

The announcement by BrainStorm follows a Notice of Allowance issued by the U.S. Patent and Trademark Office (USPTO) for the patent application (No. 14/173,846) titled “Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases.”

A Notice of Allowance indicates the invention qualifies for a patent. But additional fees and patent processes are required before the patent is fully protected. Until then, the patent is still considered as pending.

“We continue to protect our technology through strategic intellectual property [IP] achievements and this Notice of Allowance from the USPTO is a welcome addition to our IP portfolio,” Chaim Lebovits, CEO of BrainStorm, said in a press release.

The development of NurOwn started in the laboratory of Prof. Dani Offen at Tel Aviv University. Offen is currently the chief scientific adviser at BrainStorm. NurOwn is a cell therapy that uses mesenchymal stem cells (MSCs) as the therapeutic core for the treatment of neurodegenerative disorders.

MSCs are precursor cells found throughout the body, especially in fat tissue and bone marrow.

These cells produce signaling molecules that regulate the activity of other cells in their vicinity, which led researchers to investigate them as regulators of immune and inflammatory responses.

But additional studies revealed their activity was broader. One particular feature of these cells was their ability to secrete neurotrophic factors (NTF), which are involved in the growth, survival, and differentiation of nerve cells (neurons). This supported the hypothesis that MSCs could be potential modulators of neurodegeneration, while protecting neurons from damage.

Preclinical studies with mouse models of several neurodegenerative diseases, including ALS, sciatic nerve injury, Parkinson’s disease, and multiple sclerosis, confirmed the efficacy of MSCs on protecting neurons from toxin-induced damage.

In addition, results from a Phase 2 clinical trial (NCT02017912) showed that treatment with NurOwn stem cell therapy was safe and could induce clinically meaningful improvements in ALS patients. The treatment improved the patients’ functional capacity, muscle strength, and respiratory capacity, with a favorable response rate.

Currently, BrainStorm is exploring NurOwn as an ALS treatment in a Phase 3 trial(NCT03280056). The study, which is currently recruiting participants, is being conducted at six ALS clinical centers in the U.S.

https://alsnewstoday.com/2017/10/30/brainstorm-expands-patent-coverage-to-include-als-parkinsons-disease-for-nurown-therapy/